Image processing & quantitative analysis transforms raw preclinical PET/SPECT data into actionable biodistribution and dosimetry metrics. Tailored for radionuclide drug conjugates (RDCs), this service delivers end‑to‑end support, from image reconstruction and registration to region‑of‑interest (ROI) analysis, time‑activity curves, and absorbed dose calculations. Alfa Cytology provides a one‑stop solution for accurate, reproducible quantification, enabling seamless integration into RDC discovery workflows.
Image processing and quantitative analysis for RDCs involves the computational handling of nuclear medicine imaging data (PET, SPECT, and planar scintigraphy) acquired from rodent or larger animal models. This includes correction for physical effects (attenuation, scatter, decay), image registration to anatomical atlases or CT/MRI references, segmentation of organs and tumors, extraction of radioactivity concentration over time, and derivation of pharmacokinetic (PK) and dosimetry parameters. The output serves as the cornerstone for ranking RDC candidates, determining therapeutic windows, and supporting regulatory submissions.
Fig.1 Examples of amyloid PET imaging across the three radiopharmaceuticals. (Jeong, Y. J., et al., 2023)
Quantitative image analysis is critical for de‑risking RDC programs in the preclinical stage. Unlike qualitative visual inspection, rigorous quantification reveals subtle differences in tumor uptake, normal organ retention, and clearance kinetics that directly impact efficacy and off‑target toxicity. Without standardized processing, variability in reconstruction parameters, ROI delineation, and decay correction can produce misleading biodistribution profiles. Accurate quantification enables head‑to‑head comparison of linker‑chelator combinations, radionuclide variants, and dosing regimens, thereby guiding lead optimization and providing essential data for first‑in‑human dose extrapolation.
Advanced computational frameworks are utilized to handle the complexities of multi-modal data, ensuring that the final output is both reproducible and statistically significant. The methodology centers on the alignment of temporal sequences with spatial maps to track the dynamic behavior of the RDC in vivo.
Image Reconstruction & Correction
Iterative reconstruction with resolution recovery; attenuation, scatter, randoms, and decay correction specific to each isotope and acquisition protocol.
Spatial Normalization & Registration
Rigid or deformable co‑registration of PET/SPECT to high‑resolution CT or MRI; alignment to digital whole‑body phantoms for automated organ mapping.
Segmentation and ROI Definition
Utilizing automated or semi-automated algorithms to delineate Regions of Interest (ROIs) and Volumes of Interest (VOIs) for target organs and tumors.
Partial Volume Correction (PVC)
Implementing mathematical corrections to compensate for signal spillover and recovery coefficients in small structures, such as murine lymph nodes or small lesions.
Quantitative image analysis for preclinical RDC studies generates a core set of parameters that collectively define tumor targeting efficacy, normal organ toxicity risk, and radionuclide kinetics. Each parameter serves a distinct biological or dosimetric purpose, and the choice of which to report depends on the radionuclide (imaging vs. therapeutic), the study design (single time point vs. dynamic), and the regulatory or publication context. The following parameters are routinely extracted and validated.
%ID/g and SUV
%ID/g provides absolute tissue radioactivity concentration normalized to injected dose. SUV (mean/peak) offers a semi‑quantitative alternative corrected for body weight, widely used for static RDC comparisons across animals.
Tumor‑to‑Background Ratio (TBR) and Heterogeneity Index
TBR quantifies contrast between tumor and reference tissue (muscle, blood), reflecting imaging window. Heterogeneity index (SUV CoV or SUVmax/SUVmean) captures spatial uptake variation within tumor, critical for α‑emitter response.
Time‑Activity Curve (TAC) and Area Under the Curve (AUC)
TAC plots %ID/g versus time for each ROI. AUC integrates the TAC to yield time‑integrated activity concentration, serving as the foundation for dosimetry and half‑life estimation.
Residence Time
Cumulated activity per unit administered activity, expressed in hours. Derived from the AUC and decay correction. Serves as the direct input for organ‑level absorbed dose calculations using phantom or Monte Carlo methods.
Absorbed Dose (Gy/MBq)
The final dosimetric endpoint, particularly for therapeutic RDCs (e.g., ¹⁷⁷Lu, ²²⁵Ac). Combines residence time with radionuclide‑specific S‑values to predict tumor efficacy and organ‑at‑risk toxicity.
Kinetic Rate Constants (Ki, BPND, etc.)
Derived from dynamic imaging and compartmental modeling (1‑ or 2‑tissue). Ki (net influx rate) quantifies irreversible uptake; BPND (binding potential) measures specific receptor binding relative to non‑displaceable signal.
Leveraging a sophisticated bioinformatics infrastructure and deep expertise in nuclear medicine, Alfa Cytology's services deliver high-resolution spatial mapping and longitudinal data tracking for complex RDC candidates. These technical capabilities facilitate the delivery of end-to-end analytical services that accelerate the identification of lead compounds. Research partners can receive validated, submission-ready datasets that characterize the complete biological journey of a radiotracer from injection to excretion.
Alfa Cytology offers a flexible suite of image analysis services tailored to meet specific RDC program needs, ranging from basic region-based quantification to advanced pharmacokinetic modeling. All outputs are fully documented, including raw data, processing steps, and QC records, which support both internal decision-making and regulatory submissions.
ROI/VOI Quantitative Analysis
Manual, semi‑automatic, or atlas‑based delineation of regions of interest (2D) or volumes of interest (3D) for tumors, major organs, and background tissues. Extraction of mean, maximum, and standard deviation activity concentrations (kBq/cc or %ID/g) per ROI/VOI at each time point. Summary metrics include SUV parameters, tumor‑to‑background ratios, and organ‑level time‑activity curves. Suitable for static or dynamic scans with any preclinical imaging platform.
Time‑Activity Curve (TAC) Analysis
Generation of TACs for all defined ROIs/VOIs across serial scans or dynamic frame sequences. Curve fitting using mono‑exponential, bi‑exponential, or non‑compartmental models. Calculation of integrated parameters: area under the curve (AUC), half‑life of washout (t½), peak activity time (Tmax), and clearance rate constants. Data are presented as publication‑ready graphs with individual animal curves and group summaries.
Multi‑modal Image Co‑registration
Rigid and deformable registration of PET or SPECT images to high‑resolution anatomical references (CT or MRI) acquired on the same or a separate scanner. Correction for inter‑frame animal motion and cross‑modal spatial misalignment. Registration accuracy is quantitatively validated using mutual information or landmark‑based metrics. Delivered outputs include fused image volumes, transformation matrices, and registered ROI masks ready for quantitative extraction.
Dynamic Pharmacokinetic Modeling
Compartmental modeling of dynamic PET or SPECT data (typically 30–60 minutes scans with multiple frames). Model selection (1‑tissue, 2‑tissue reversible/irreversible) guided by Akaike information criterion and residual analysis. Estimation of rate constants: K₁ (influx), k₂ (efflux), k₃ (binding), k₄ (dissociation), net influx rate Ki, and binding potential BPND. Suitable for RDCs with reversible or internalizing targets, providing mechanistic insight beyond simple SUV or %ID/g.
Alfa Cytology's comprehensive, validated image processing and quantitative analysis services transform preclinical RDC imaging data into decision‑driving metrics, from SUV and TAC to organ‑level dosimetry. Every step, from reconstruction to final report, is executed with isotope‑specific rigor and full traceability. For a detailed quote or to discuss a specific data analysis challenge, please contact us.
Reference
For research use only. Not intended for any clinical use.
Alfa Cytology, a provider of RDC preclinical services, specializes in RDC design, conjugation, and analysis. Supported by a rich library of radionuclides, chelators, and linkers, we excel in targeting molecule design. We offer customized RDC services tailored to diverse requirements-your demand is our mission.
Copyright © 2026 Alfa Cytology. All rights reserved.